PRS22 THE COST EFFECTIVENESS OF DORNASE ALFA VERSUS INHALED TOBRAMYCIN IN THE MANAGEMENT OF PATIENTS WITH CYSTIC FIBROSIS

Abstract

Authors

S. Rezaei S. Taheri N. Yousefi F. Peiravian

Full Text Cite This Article
Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×